Mostrar registro simples

dc.contributor.authorKhan, Aqib Hassan Ali 
dc.contributor.authorBarros García, Rocío 
dc.date.accessioned2023-06-27T09:59:13Z
dc.date.available2023-06-27T09:59:13Z
dc.date.issued2023-06
dc.identifier.issn2673-9917
dc.identifier.urihttp://hdl.handle.net/10259/7719
dc.descriptionThis article belongs to the Special Issue "Feature Papers in Hydrobiology 2022–2023"en
dc.description.abstractThe presence of pharmaceuticals in the aquatic environment presents a challenge to modern science. The most significant impact this can induce is the emergence of antibiotic resistance, which can lead to a global health emergency. It is important to note that the impact of pharmaceuticals in the aquatic environment is not limited to antibiotic resistance. Pharmaceuticals can also affect the behaviour and reproductive systems of aquatic organisms, with cascading effects on entire ecosystems. Numerous studies have reported the emergence of pharmaceuticals due to the uncontrolled disposal of polluted domestic, agricultural, and industrial wastewater in water bodies. This work discusses the potential of pharmaceuticals that on one hand are highly important for mankind, yet their non-judicious usage and disposal induce equally intriguing and problematic conditions to the health of aquatic systems. Pathways through which pharmaceutics can make their way into water bodies are discussed. Furthermore, the risk imposed by pharmaceuticals on aquatic life is also elaborated. The possible and pragmatic remediation methods through which pharmaceutical products can be treated are also discussed. Emphasis is placed on the potential of phytoremediation and advanced oxidative process, and the factors affecting the efficacy of these remediation methods are discussed.en
dc.description.sponsorshipThe authors want to acknowledge the funding received under GREENER and BIOSYSMO projects. The GREENER project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Grant Agreement No. 826312, while the BIOSYSMO project is funded by the European Union under the Grant Agreement No. 101060211.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofHydrobiology. 2023, V. 2, n. 2, p. 395-409en
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPharmaceuticalsen
dc.subjectaquatic ecosystemsen
dc.subjectHydrobiologyen
dc.subjectPhytoremediationen
dc.subjectAdvance oxidative processesen
dc.subject.otherBioquímicaes
dc.subject.otherBiochemistryen
dc.subject.otherMicrobiologíaes
dc.subject.otherMicrobiologyen
dc.titlePharmaceuticals in Water: Risks to Aquatic Life and Remediation Strategiesen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.3390/hydrobiology2020026es
dc.identifier.doi10.3390/hydrobiology2020026
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/826312/EU/InteGRated systems for Effective ENvironmEntal Remediation/GREENER/en
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/HE/101060211/EU/BIOremediation systems exploiting SYnergieS for improved removal of Mixed pOllutants/BIOSYSMOen
dc.identifier.essn2673-9917
dc.journal.titleHydrobiologyen
dc.volume.number2es
dc.issue.number2es
dc.page.initial395es
dc.page.final409es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Arquivos deste item

Thumbnail

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples